Fig. 5
Deposition of 125I-fibrin(ogen) in organs of mice treated with LPS and L-NAME. Mice were treated with or without (No LPS/L-NAME) multiple intraperitoneal (IP) injections of LPS and L-NAME. Immediately prior to the IP injection, all mice were injected intravenously with 125I-fibrinogen in saline vehicle, alone (Vehicle) or combined with 40 mg/kg body weight EPR-HV3HSA or mycHV3HSA. Five hours later, mice were euthanized and the radioactivity present in excised hearts (panels a and c) or kidneys (panels b and d) was determined and expressed as the % of the injected dose (panels a and b) or normalized to the mean of the % of the injected dose in the No LPS/L-NAME cohort (panels c and d). Bars depict the mean of 5 determinations, each in a separate mouse, ± SD. Lines above bars show statistical significance between groups as determined by ANOVA with post-tests (p < 0.5, *, p < 0.01, **, p < 0.001, ***). Scatter plots (c and d) show the same data as in a and b, except that each point corresponds to data from a single mouse, normalized to the “No LPS/L-NAME” control